why choose us

First received: November 01, 2023

Clinical Trial: Drug Nephrotoxicity Amelioration by N-acetylcysteine

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Drug-Induced Nephropathy

Study Type: INTERVENTIONAL


Official Title: Drug Nephrotoxicity Amelioration in Hematological Malignancies Patients by N-acetylcysteine

Brief Summary: When treating individuals with febrile neutropenia, amphotericin B (AmB-d) is one of the most effective treatments against often fatal systemic fungal infections.Nephrotoxicity from amphotericin B can develop with an incidence of up to 80.This emphasizes the value of nephroprotectant agent use.Because of N-acetylcysteine's antioxidant, antiapoptotic, vasodilator properties and its therapeutic effects on contrast nephropathy.Acetylcysteine's impact on amphotericin B-induced nephrotoxicity in cancer…

Read more